ADMA Biologics
ADMA
24 hedge funds and large institutions have $65.4M invested in ADMA Biologics in 2015 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
146% more capital inflows, than outflows
Capital inflows: $1.04M | Capital outflows: $422K
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.23% less ownership
Funds ownership: 75.23% → 66% (-9.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$417K |
| 2 |
Weiss Multi-Strategy Advisers
New York
|
+$319K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$119K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$64K |
| 5 |
TI
Telemetry Investments
New York
|
+$31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$294K |
| 2 |
UBS O'Connor
Chicago,
Illinois
|
-$79.6K |
| 3 |
SIM
Spark Investment Management
New York
|
-$22.5K |
| 4 |
Goldman Sachs
New York
|
-$21.3K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$4.36K |
ADMA Hedge Fund Activity: Q2 2015 in Review
24 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2015, worth a combined $65.4M — down 4.5% from $68.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ADMA positions and 1 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $417K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $294K sold.
- 24 institutional investors held ADMA Biologics (ADMA) as of Q2 2015, up from 19 in Q1 2015.
- Funds reported $65.4M of ADMA Biologics stock for Q2 2015, down 4.5% quarter-over-quarter.
- 6 funds opened new ADMA Biologics positions in Q2 2015 and 1 closed out, a net change of +5 holders.
- The largest ADMA Biologics buyer in Q2 2015 was Consonance Capital Management, an estimated $417K added.
- The largest ADMA Biologics seller in Q2 2015 was Susquehanna International Group, an estimated $294K sold.
Based on aggregated 13F filings for Q2 2015.